<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01063101</url>
  </required_header>
  <id_info>
    <org_study_id>950901</org_study_id>
    <nct_id>NCT01063101</nct_id>
  </id_info>
  <brief_title>Phase 1 Dosing Study of BAX 513 in Healthy Volunteers</brief_title>
  <official_title>A Phase 1 Study to Evaluate the Effects of BAX 513 on Hemostatic Parameters in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxalta now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate whether orally administered BAX 513 (different
      doses administered for 5 days) affects hemostatic parameters in healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 29, 2010</start_date>
  <completion_date type="Actual">August 1, 2010</completion_date>
  <primary_completion_date type="Actual">July 22, 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in peak thrombin concentration from baseline as measured by the Thrombin Generation Assay (TGA).</measure>
    <time_frame>7 months (= anticipated study duration)</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>BAX 513</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsule - one of 5 dose levels (per randomization) - BID (= twice a day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Capsule (cellulose)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Capsule - one of 5 dose levels (per randomization) - BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fucoidan (extract of Laminaria japonica)</intervention_name>
    <description>Capsule (300 mg/capsule) - oral administration - 5 different dose levels - BID</description>
    <arm_group_label>BAX 513</arm_group_label>
    <other_name>BAX 513</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Cellulose filled capsule - oral administration - 5 different dose levels - BID</description>
    <arm_group_label>Capsule (cellulose)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is &gt;= 18 and &lt; 70 years old at the time of screening

          -  Is able to provide signed and dated informed consent

          -  Is a healthy male or female adult

          -  If female and of childbearing potential, subject demonstrates a negative serum
             pregnancy test, and agrees to employ adequate birth control measures; (e.g., oral
             contraceptives, barrier method) for the duration of the study

          -  If female and receiving hormone replacement therapy (HRT), subject agrees to abstain
             from HRT for the duration of the study

          -  Subject's medical history and physical exam are normal

          -  Subject's lab values for complete blood count (CBC) and clinical chemistry are within
             normal ranges

          -  Is able to comprehend and comply with all aspects of the protocol and signed informed
             consent

        Exclusion Criteria:

          -  If female, subject is pregnant or lactating at the time of study enrollment

          -  Has participated in another clinical study involving an investigational product (IP)
             or device within 30 days of screening or is scheduled to participate in another
             clinical study involving an IP or device during the course of this study

          -  Has a history of drug allergy in general or hypersensitivity to fucoidan containing
             products/foods or seafoods

          -  Medical and/or family history of thrombophilic tendencies, eg Protein C or
             S-deficiency, ATIII deficiency, FV Leiden mutation, Prothrombin 20210A mutation, lupus
             type inhibitor, antiphospholipid antibodies

          -  Medical history or clinical findings of a significant bleeding disorder

          -  Medical history of thrombotic events such as venous thromboembolism (VTE), myocardial
             infarction (MI), stroke or transient ischemic attack (TIA)

          -  Any other clinically relevant history of disease, eg malabsorption disorders,
             malignancies

          -  Any clinically significant abnormal laboratory values or abnormal ECG findings that in
             the opinion of the investigator are considered clinically relevant

          -  Seropositivity for HBs-Ag, HCV, HIV-1 or HIV-2 antibodies

          -  Symptoms of a clinically relevant illness within 3 weeks before screening

          -  A history of, or suspected, drug or alcohol abuse, or subject tests positive on a
             Drugs of Abuse screen within 1 week of dosing

          -  Intake of IP or related (fucoidan-containing) product within 1 week prior to study
             enrollment

          -  Any planned surgical or dental procedure during the course of this study

          -  Any recent surgery within 30 days of enrollment

          -  Presence of signs or symptoms consistent with an infection, such as fever, chills, or
             nausea during screening in this study

          -  Chronic or regular use of aspirin, ibuprofen, coumarin derivatives, antiplatelet
             drugs, within 1 week before enrollment

          -  Use of concomitant drugs diclofenac or [paracetamol if &gt; 2 g/day] within 1 week before
             first day of study dosing

          -  Plasmapheresis or platelet donation within 3 weeks of screening and until final visit

          -  Any medical condition that may compromise the ability to give written informed consent
             or to comply with the study protocol

          -  Subject is a member of the team conducting the study or in a dependent relationship
             with one of the study team members. Dependent relationships include close relatives
             (ie, children, partner/spouse, siblings, parents) as well as employees of the
             investigator or site personnel conducting the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wing-Yen Wong, MD</last_name>
    <role>Study Director</role>
    <affiliation>Baxter Healthcare Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Clinic for Clinical Pharmacology, General Hospital Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2010</study_first_submitted>
  <study_first_submitted_qc>February 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2010</study_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <name_title>Wing-Yen Wong, MD; Medical Director</name_title>
    <organization>Baxter Healthcare Corporation</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fucoidan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

